Analyst Price Targets — QNCX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 20, 2026 11:20 am | — | Craig-Hallum | $68.00 | $34.57 | TheFly | Quince Therapeutics initiated with a Buy at Craig-Hallum |
| August 18, 2026 1:00 pm | Olivia Brayer Saunders | Cantor Fitzgerald | $70.00 | $32.91 | StreetInsider | Cantor Fitzgerald Reiterates Overweight Rating on Quince Therapeutics Inc. (QNCX) |
Latest News for QNCX
Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline
SOUTH SAN FRANCISCO, Calif. , June 30, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced the formation of a Scientific Advisory Board (SAB) of leading clinicians to support the advancement of LAM-001, an inhaled formulation of rapamycin (mTOR…
SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced the formation of a Scientific Advisory Board (SAB) of leading clinicians to support the advancement of LAM-001, an inhaled formulation of rapamycin (mTOR…
Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for QNCX.
U.S. House Trading
No House trades found for QNCX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.